title: [Recent advances in the treatment of the acute hepatitis C].
abstract: Acute hepatitis C is characterized by a frequent evolution in chronic form (70-85% of cases). The recent literature evidences that Peg-interferon alpha-2b is efficacy for the treatment of acute hepatitis C (90% of sustained response). Treatment, independently by HCV genotype and baseline viral load, must be prolonged for three months and it must be started into three months by onset.
authors.affiliation: Dipartimento Materno Infantile, Ospedale di Sondrio.
authors.forename: Emilio
authors.initials: E
authors.lastname: Palumbo
mesh_terms: D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b